3M Ducks Contract Suit Over $854M Pharma Unit Sale

Law360, Los Angeles (September 04, 2013, 5:04 PM ET) -- A New York federal judge on Monday ruled that 3M Co. hadn't violated an $854 million deal selling its European pharmaceutical business to Meda AB when it failed to disclose that its top-selling drug was due for a price reduction, finding Meda hadn't adequately performed due diligence.

Meda had argued that 3M violated several warranties in the acquisition agreement by failing to disclose during negotiations that its top-selling anti-arrhythmic drug, Flecaine, was subject to a government-mandated price reduction in France. But U.S. District Judge Alison J....
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers


Case Information

Case Title

Meda AB v. 3M Company et al

Case Number



New York Southern

Nature of Suit

Contract: Other


Alison J. Nathan

Date Filed

January 20, 2011


Law Firms Mentioned

Companies Mentioned

Related Articles